Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea
- PMID: 21037487
- DOI: 10.1097/gme.0b013e3181f3e6e7
Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea
Abstract
Objective: The objective of our study was to show the impact of different chemotherapy regimens on the incidence of amenorrhea (chemotherapy-induced amenorrhea [CIA]) in premenopausal women of various ages with breast cancer.
Methods: This is a follow-up study of 226 premenopausal women with breast cancer who had received one of three chemotherapy regimens: conventional (cyclophosphamide/methotrexate/5-fluorouracil), anthracycline based, and anthracycline-taxane based. They were evaluated for the incidence of CIA in the follow-up clinic of the Iranian Center for Breast Cancer. A statistical analysis using SPSS software was performed, and logistic regression and Cox regression model were used to determine the risk factors for CIA.
Results: Of the 226 women with a median age of 40 years (range, 26-56 y) who participated in this study, 154 (68.1%) developed CIA. In 101 (65.6%) of these women, CIA was established. CIA was present in 52.5% of the women who had been treated with conventional regimens (cyclophosphamide/methotrexate/5-fluorouracil), 66.7% of the women who had been treated with anthracycline, and 78.7% of the women who had been treated with anthracycline-taxane. Therefore, the frequency of CIA was significantly higher in the taxane-based chemotherapy group than in the other groups (P = 0.015). Although a slightly higher incidence of CIA in women with hormone-insensitive tumors (estrogen receptor negative and progesterone receptor negative) versus hormone-sensitive tumors (estrogen receptor positive and progesterone receptor positive) who had been treated with combination regimens was observed, no statistically significant difference was found (P = 0.629). Of all of the risk factors that were evaluated in the study, anthracycline-taxane-based regimens (odds ratio, 4.059; 95% CI, 1.6-9.8) and age older than 40 years (odds ratio, 3.5; 95% CI, 1.9-6.6) were the most important factors in the development of CIA.
Conclusions: The type of chemotherapy and the age of the woman at the onset of breast cancer are the most important risk factors in CIA. Taxane-based regimens induced more CIA than did other regimens.
Similar articles
-
Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.Breast Cancer Res Treat. 2010 Feb;120(1):245-51. doi: 10.1007/s10549-009-0426-x. Epub 2009 Jul 3. Breast Cancer Res Treat. 2010. PMID: 19575291
-
Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane.Breast Cancer. 2011 Jul;18(3):182-8. doi: 10.1007/s12282-011-0256-7. Epub 2011 Mar 11. Breast Cancer. 2011. PMID: 21394515
-
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.Breast Cancer Res Treat. 2020 Jul;182(2):325-332. doi: 10.1007/s10549-020-05692-5. Epub 2020 May 28. Breast Cancer Res Treat. 2020. PMID: 32462261 Clinical Trial.
-
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.Lancet Oncol. 2005 Nov;6(11):886-98. doi: 10.1016/S1470-2045(05)70424-1. Lancet Oncol. 2005. PMID: 16257797 Review.
-
Adjuvant treatments for triple-negative breast cancers.Ann Oncol. 2012 Aug;23 Suppl 6:vi40-5. doi: 10.1093/annonc/mds194. Ann Oncol. 2012. PMID: 23012301 Review.
Cited by
-
SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.BMC Cancer. 2016 May 27;16:337. doi: 10.1186/s12885-016-2373-3. BMC Cancer. 2016. PMID: 27234217 Free PMC article.
-
Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients.Medicine (Baltimore). 2016 Apr;95(14):e3301. doi: 10.1097/MD.0000000000003301. Medicine (Baltimore). 2016. PMID: 27057900 Free PMC article.
-
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16. Breast Cancer Res Treat. 2015. PMID: 25981899 Free PMC article.
-
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy.Breast Cancer Res. 2024 Nov 5;26(1):152. doi: 10.1186/s13058-024-01903-9. Breast Cancer Res. 2024. PMID: 39501399 Free PMC article. Clinical Trial.
-
Cancer Treatment-Related Infertility: A Critical Review of the Evidence.JNCI Cancer Spectr. 2019 Apr 9;3(1):pkz008. doi: 10.1093/jncics/pkz008. eCollection 2019 Mar. JNCI Cancer Spectr. 2019. PMID: 31360893 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials